Dr. Ansell on Promising Combinations Being Studied in MCL

Stephen M. Ansell, MD, PhD
Published: Wednesday, May 17, 2017



Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

There are several clinical trials exploring combination regimens in MCL, one of which is lenalidomide (Revlimid) and rituximab (Rituxan) in the frontline setting, Ansell explains. The exciting part of this study, he adds, is that the response rates have been high in patients receiving the combination. This has also challenged researchers' thinking that they only need to use aggressive treatments.

Immunotherapy could also have potential in treating these patients, he says. The current challenge, however, is that there are little data on how well immune checkpoint therapies work in MCL. Prior clinical studies included a small portion of patients with MCL, and there has not really been an MCL-focused trial. Many trials are ongoing, so longer follow-up will determine whether this is a promising treatment, he adds.
SELECTED
LANGUAGE


Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

There are several clinical trials exploring combination regimens in MCL, one of which is lenalidomide (Revlimid) and rituximab (Rituxan) in the frontline setting, Ansell explains. The exciting part of this study, he adds, is that the response rates have been high in patients receiving the combination. This has also challenged researchers' thinking that they only need to use aggressive treatments.

Immunotherapy could also have potential in treating these patients, he says. The current challenge, however, is that there are little data on how well immune checkpoint therapies work in MCL. Prior clinical studies included a small portion of patients with MCL, and there has not really been an MCL-focused trial. Many trials are ongoing, so longer follow-up will determine whether this is a promising treatment, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x